Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer
Public ClinicalTrials.gov record NCT02369874. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 Monotherapy and MEDI4736 in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Study identification
- NCT ID
- NCT02369874
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- AstraZeneca
- Industry
- Enrollment
- 736 participants
Conditions and interventions
Interventions
- MEDI4736 Drug
- MEDI4736 + Tremelimumab Drug
- Standard of Care Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 96 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 8, 2015
- Primary completion
- Sep 9, 2018
- Completion
- Nov 12, 2020
- Last update posted
- Feb 9, 2021
2015 – 2020
United States locations
- U.S. sites
- 23
- U.S. states
- 15
- U.S. cities
- 21
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Tucson | Arizona | 85711 | — |
| Research Site | Fullerton | California | 92835-3825 | — |
| Research Site | Los Angeles | California | 90089 | — |
| Research Site | Redondo Beach | California | 90277 | — |
| Research Site | Stanford | California | 94305 | — |
| Research Site | Denver | Colorado | 80218 | — |
| Research Site | Newark | Delaware | 19713 | — |
| Research Site | Miami Beach | Florida | 33140 | — |
| Research Site | Orlando | Florida | 32806 | — |
| Research Site | Atlanta | Georgia | 30322 | — |
| Research Site | Evanston | Illinois | 60201-1718 | — |
| Research Site | Lexington | Kentucky | 40536 | — |
| Research Site | Boston | Massachusetts | 02215 | — |
| Research Site | Rochester | New York | 14621 | — |
| Research Site | Rochester | New York | 14642 | — |
| Research Site | Winston-Salem | North Carolina | 27157 | — |
| Research Site | Pittsburgh | Pennsylvania | 15232 | — |
| Research Site | Germantown | Tennessee | 38138 | — |
| Research Site | Nashville | Tennessee | 37232 | — |
| Research Site | Dallas | Texas | 75230 | — |
| Research Site | Dallas | Texas | 75246 | — |
| Research Site | McAllen | Texas | 78503 | — |
| Research Site | Norfolk | Virginia | 23502 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 145 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02369874, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 9, 2021 · Synced Jun 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02369874 live on ClinicalTrials.gov.